Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine add-on therapy for moderate COVID-19
2020-002299-11Phase 2Terminated
- Sponsor
- SigmaDrugs Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Fluvoxamine + standard of care with Placebo + standard of care (2 arms). Started Jun 2020; status: terminated.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002299-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002299-11.